{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:18:08Z","timestamp":1765279088188,"version":"3.37.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["1F31MH114465-01"],"award-info":[{"award-number":["1F31MH114465-01"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jdiacomp.2017.12.008","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T18:41:50Z","timestamp":1514400110000},"page":"492-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression"],"prefix":"10.1016","volume":"32","author":[{"given":"Shan","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex D.","family":"Leow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8971-0102","authenticated-orcid":false,"given":"Shiyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen T.","family":"Schumock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Touchette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdiacomp.2017.12.008_bb0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11606-016-3650-1","article-title":"Trends in costs of depression in adults with diabetes in the United States: Medical Expenditure Panel Survey, 2004\u20132011","volume":"31","author":"Egede","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0010","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0165-0327(12)70009-5","article-title":"Co-occurrence of diabetes and depression: conceptual considerations for an emerging global health challenge","volume":"142","author":"Fisher","year":"2012","journal-title":"J Affect Disord"},{"issue":"12","key":"10.1016\/j.jdiacomp.2017.12.008_bb0015","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.2337\/dc08-1341","article-title":"Depression and diabetes treatment nonadherence: a meta-analysis","volume":"31","author":"Gonzalez","year":"2008","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.jdiacomp.2017.12.008_bb0020","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1464-5491.2008.02535.x","article-title":"Symptoms of depression prospectively predict poorer self-care in patients with type 2 diabetes","volume":"25","author":"Gonzalez","year":"2008","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.jdiacomp.2017.12.008_bb0025","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-8587(15)00045-5","article-title":"Depression and diabetes: treatment and health-care delivery","volume":"3","author":"Petrak","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0030","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0165-0327(12)70004-6","article-title":"Epidemiology of depression and diabetes: a systematic review","volume":"142","author":"Roy","year":"2012","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.12.008_bb0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4088\/JCP.13m08675","article-title":"National trends in second-generation antipsychotic augmentation for nonpsychotic depression","volume":"75","author":"Gerhard","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0040","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.jdiacomp.2017.12.008_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and alternative medicine treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0050","article-title":"Second-generation antipsychotics for major depressive disorder and dysthymia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2010.11.007","article-title":"Treating depression in diabetes: emerging findings","volume":"52","author":"Markowitz","year":"2011","journal-title":"Psychosomatics"},{"issue":"10","key":"10.1016\/j.jdiacomp.2017.12.008_bb0060","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.2337\/dc13-0560","article-title":"Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review","volume":"36","author":"Barnard","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jdiacomp.2017.12.008_bb0065","article-title":"Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression","volume":"12","author":"Baumeister","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/fampra\/cmv100","article-title":"Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression","volume":"33","author":"Brieler","year":"2016","journal-title":"Fam Pract"},{"issue":"11","key":"10.1016\/j.jdiacomp.2017.12.008_bb0075","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1016\/S0149-2918(03)80347-8","article-title":"Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study","volume":"25","author":"Balkrishnan","year":"2003","journal-title":"Clin Ther"},{"issue":"17","key":"10.1016\/j.jdiacomp.2017.12.008_bb0080","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","article-title":"Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0085","first-page":"71","article-title":"Oral antidiabetic medication adherence and glycemic control in managed care","volume":"14","author":"Rozenfeld","year":"2008","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ps.201300118","article-title":"Adherence to oral diabetes medications among users and nonusers of antipsychotic medication","volume":"65","author":"Desai","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"3","key":"10.1016\/j.jdiacomp.2017.12.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.12.008_bb0100","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis","volume":"76","author":"Zhou","year":"2015","journal-title":"J Clin Psychiatry"},{"author":"Hansen","key":"10.1016\/j.jdiacomp.2017.12.008_bb0105"},{"author":"Centers for Medicare and Medicaid Services (CMS)","key":"10.1016\/j.jdiacomp.2017.12.008_bb0110"},{"issue":"10","key":"10.1016\/j.jdiacomp.2017.12.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075256","article-title":"Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records","volume":"8","author":"Leong","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12888-014-0289-5","article-title":"Systematic review and assessment of validated case definitions for depression in administrative data","volume":"14","author":"Fiest","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"12","key":"10.1016\/j.jdiacomp.2017.12.008_bb0125","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1176\/appi.ps.005482012","article-title":"Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population","volume":"64","author":"Hartung","year":"2013","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11096-016-0272-y","article-title":"Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression","volume":"38","author":"Hassan","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"10.1016\/j.jdiacomp.2017.12.008_bb0135","first-page":"457","article-title":"Measuring concurrent adherence to multiple related medications","volume":"15","author":"Choudhry","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0140","first-page":"1294","article-title":"A comparison of data driven-based measures of adherence to oral hypoglycemic agents in Medicaid patients","volume":"2014","author":"Zhu","year":"2014","journal-title":"AMIA Annu Symp Proc"},{"issue":"8","key":"10.1016\/j.jdiacomp.2017.12.008_bb0145","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1377\/hlthaff.2011.1198","article-title":"Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually","volume":"31","author":"Jha","year":"2012","journal-title":"Health Aff"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/dme.12651","article-title":"Adherence to diabetes medication: a systematic review","author":"Krass","year":"2015","journal-title":"Diabet Med"},{"issue":"11","key":"10.1016\/j.jdiacomp.2017.12.008_bb0155","first-page":"1293","article-title":"Risk of nonadherence to diabetes medications among Medicare advantage enrollees: development of a validated risk prediction tool","volume":"22","author":"Mhatre","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.jdiacomp.2017.12.008_bb0160","first-page":"370","article-title":"Cost burden of treatment resistance in patients with depression","volume":"16","author":"Gibson","year":"2010","journal-title":"Am J Manag Care"},{"issue":"2016","key":"10.1016\/j.jdiacomp.2017.12.008_bb0165","first-page":"1","article-title":"Does the use of atypical antipsychotics as adjunctive therapy in depression result in cost savings? Comparing healthcare costs and utilization between second-line treatment options","volume":"8237","author":"Hassan","year":"2015","journal-title":"J Ment Health"},{"issue":"9","key":"10.1016\/j.jdiacomp.2017.12.008_bb0170","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.clinthera.2011.07.015","article-title":"Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression","volume":"33","author":"Jing","year":"2011","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.jdiacomp.2017.12.008_bb0175","first-page":"721","article-title":"Validating the adapted diabetes complications severity index in claims data","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0180","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization","volume":"14","author":"Young","year":"2008","journal-title":"Am J Manag Care"},{"author":"Pharmacy Quality Alliance","key":"10.1016\/j.jdiacomp.2017.12.008_bb0185"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity","volume":"65","author":"American Diabetes Association","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0195","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/schbul\/sbn106","article-title":"Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr Bull"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2011.03.013","article-title":"A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness","volume":"188","author":"Kreyenbuhl","year":"2011","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.1016\/j.jdiacomp.2017.12.008_bb0205","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.psym.2011.03.004","article-title":"Adherence to antihyperlipidemic medication and lipid control in diabetic veterans affairs patients with psychotic disorders","volume":"52","author":"Nelson","year":"2011","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/YCO.0b013e3283413505","article-title":"Second-generation antipsychotics in major depressive disorder: update and clinical perspective","volume":"24","author":"Chen","year":"2011","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.jdiacomp.2017.12.008_bb0220","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/phar.1204","article-title":"Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature","volume":"33","author":"Wright","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jdiacomp.2017.12.008_bb0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0000000000000663","article-title":"Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study","volume":"37","author":"Cheon","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0235","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpsychires.2015.04.020","article-title":"Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study","volume":"66\u201367","author":"Han","year":"2015","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0240","doi-asserted-by":"crossref","unstructured":"Al-Ruthia, Y. S., Hong, S. H., & Solomon, D. (n.d.). Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. Res Soc Adm Pharm, 11(2), 228\u201340. https:\/\/doi.org\/10.1016\/j.sapharm.2014.06.001.","DOI":"10.1016\/j.sapharm.2014.06.001"},{"key":"10.1016\/j.jdiacomp.2017.12.008_bb0245","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-016-0272-y","article-title":"Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression","author":"Hassan","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0250","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18553\/jmcp.2014.20.1.76","article-title":"Comparative assessment of adherence measures and resource use in SSRI\/SNRI-treated patients with depression using second-generation antipsychotics or l-methylfolate as adjunctive therapy","volume":"20","author":"Wade","year":"2014","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"10.1016\/j.jdiacomp.2017.12.008_bb0255","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14737175.2013.811901","article-title":"Second-generation antipsychotics in the treatment of major depressive disorder: current evidence","volume":"13","author":"Han","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"suppl 1","key":"10.1016\/j.jdiacomp.2017.12.008_bb0260","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/s40263-012-0032-z","article-title":"Clinical issues in use of atypical antipsychotics for depressed patients","volume":"27","author":"Pae","year":"2013","journal-title":"CNS Drugs"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872717307468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872717307468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T06:15:42Z","timestamp":1668752142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872717307468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1056872717307468"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.12.008","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}